Abstract

Autoimmune diseases result from a dysfunctional immune system in which the body attacks its own organs, tissues, cells, and macromolecules. This group of diseases consists of more than 80 chronic diseases that often lead to disabilities. Targeting therapy for autoimmune diseases faces two major challenges: (1) identification of autoreactive cells that can be targeted for suppression; and (2) penetration through target tissues to specifically deliver drugs to the desired cells and thus to achieve sufficient therapeutic efficacy. Regarding the latter, multiple drug delivery approaches have been developed. In the present work, the current nanomedicine development strategies for the improved treatment of several common autoimmune diseases are reviewed.

Original languageEnglish (US)
Pages (from-to)703-716
Number of pages14
JournalDrug Development Research
Volume72
Issue number8
DOIs
StatePublished - Dec 1 2011

Fingerprint

Nanomedicine
Autoimmune Diseases
Pharmaceutical Preparations
Immune System
Chronic Disease
Therapeutics

Keywords

  • PEGylation technique
  • autoimmune diseases
  • host cell-encapsulated islet cell graft
  • liposomal drug delivery
  • nanomedicine
  • siRNA polycomplex

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Nanomedicine development for autoimmune diseases. / Yuan, Fang; Thiele, Geoffrey Milton; Wang, Dong.

In: Drug Development Research, Vol. 72, No. 8, 01.12.2011, p. 703-716.

Research output: Contribution to journalReview article

@article{c5714d4cf3904d36a7048d694b0b7cc6,
title = "Nanomedicine development for autoimmune diseases",
abstract = "Autoimmune diseases result from a dysfunctional immune system in which the body attacks its own organs, tissues, cells, and macromolecules. This group of diseases consists of more than 80 chronic diseases that often lead to disabilities. Targeting therapy for autoimmune diseases faces two major challenges: (1) identification of autoreactive cells that can be targeted for suppression; and (2) penetration through target tissues to specifically deliver drugs to the desired cells and thus to achieve sufficient therapeutic efficacy. Regarding the latter, multiple drug delivery approaches have been developed. In the present work, the current nanomedicine development strategies for the improved treatment of several common autoimmune diseases are reviewed.",
keywords = "PEGylation technique, autoimmune diseases, host cell-encapsulated islet cell graft, liposomal drug delivery, nanomedicine, siRNA polycomplex",
author = "Fang Yuan and Thiele, {Geoffrey Milton} and Dong Wang",
year = "2011",
month = "12",
day = "1",
doi = "10.1002/ddr.20479",
language = "English (US)",
volume = "72",
pages = "703--716",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Nanomedicine development for autoimmune diseases

AU - Yuan, Fang

AU - Thiele, Geoffrey Milton

AU - Wang, Dong

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Autoimmune diseases result from a dysfunctional immune system in which the body attacks its own organs, tissues, cells, and macromolecules. This group of diseases consists of more than 80 chronic diseases that often lead to disabilities. Targeting therapy for autoimmune diseases faces two major challenges: (1) identification of autoreactive cells that can be targeted for suppression; and (2) penetration through target tissues to specifically deliver drugs to the desired cells and thus to achieve sufficient therapeutic efficacy. Regarding the latter, multiple drug delivery approaches have been developed. In the present work, the current nanomedicine development strategies for the improved treatment of several common autoimmune diseases are reviewed.

AB - Autoimmune diseases result from a dysfunctional immune system in which the body attacks its own organs, tissues, cells, and macromolecules. This group of diseases consists of more than 80 chronic diseases that often lead to disabilities. Targeting therapy for autoimmune diseases faces two major challenges: (1) identification of autoreactive cells that can be targeted for suppression; and (2) penetration through target tissues to specifically deliver drugs to the desired cells and thus to achieve sufficient therapeutic efficacy. Regarding the latter, multiple drug delivery approaches have been developed. In the present work, the current nanomedicine development strategies for the improved treatment of several common autoimmune diseases are reviewed.

KW - PEGylation technique

KW - autoimmune diseases

KW - host cell-encapsulated islet cell graft

KW - liposomal drug delivery

KW - nanomedicine

KW - siRNA polycomplex

UR - http://www.scopus.com/inward/record.url?scp=83655191773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83655191773&partnerID=8YFLogxK

U2 - 10.1002/ddr.20479

DO - 10.1002/ddr.20479

M3 - Review article

AN - SCOPUS:83655191773

VL - 72

SP - 703

EP - 716

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 8

ER -